Teva Pharmaceutical Industries Beheer
Beheer criteriumcontroles 2/4
De CEO Teva Pharmaceutical Industries is Richard Francis, benoemd in Jan2023, heeft een ambtstermijn van 1.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 25.71M, bestaande uit 6.2% salaris en 93.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.011% van de aandelen van het bedrijf, ter waarde $ 2.31M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.7 jaar en 7.3 jaar.
Belangrijke informatie
Richard Francis
Algemeen directeur
US$25.7m
Totale compensatie
| Percentage CEO-salaris | 6.2% |
| Dienstverband CEO | 1.8yrs |
| Eigendom CEO | 0.01% |
| Management gemiddelde ambtstermijn | 2.7yrs |
| Gemiddelde ambtstermijn bestuur | 7.3yrs |
Recente managementupdates
Recent updates
Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt
Oct 23Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?
Oct 21
Cheap Teva Stock Should Reward Patient Investors
Sep 09Teva's Transformation: From Generics Leader To Branded Drug Innovator
Aug 14Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 02Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs
Jul 26Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Jul 12Teva Pharmaceutical: Buy This Bargain Before It's Gone
Jun 07Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
May 14Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)
May 09Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26Teva Pharmaceutical Industries: Potential Outweighs Concerns
Mar 25Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
Feb 26A Review Of Teva's Prospects
Feb 15Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry
Jan 07These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way
Dec 11Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)
Dec 08Teva: Deeply Undervalued FCF Machine
Nov 20Teva: Focus On Innovation And Growth Means The Times They Are A Changing
Sep 14Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt
Sep 09The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
Aug 26Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain
Aug 02Teva Pharmaceutical: Lacking Capabilities For Strategic Investments
Jul 20Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence
Jun 15Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load
Jun 06Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Feb 20What To Expect From Teva Pharmaceutical In 2023 With A New CEO
Feb 15Can Teva Pharmaceutical's Q4 results bring positive surprise?
Feb 07Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment
Jan 19Tamiflu supplies released from national stockpile as nationwide shortage persists
Jan 12Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year
Dec 28Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex
Dec 16Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit
Nov 10Teva Pharmaceutical to pay New York $523M as part of opioid settlement
Nov 03Teva data indicates long-term benefit of Austedo for chorea associated with Huntington's
Oct 18Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$453m |
| Mar 31 2024 | n/a | n/a | -US$478m |
| Dec 31 2023 | US$26m | US$2m | -US$559m |
Compensatie versus markt: De totale vergoeding ($USD 25.71M ) Richard } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.86M ).
Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Richard te vergelijken met de prestaties van het bedrijf.
CEO
Richard Francis (56 yo)
1.8yrs
Tenure
US$25,706,880
Compensatie
Mr. Richard D. Francis serves as President and Chief Executive Officer at Teva Pharmaceutical Industries Limited since January 01, 2022 and serves as its Director. Mr. Francis served as Division Head and C...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 1.8yrs | US$25.71m | 0.011% $ 2.3m | |
| Executive VP & CFO | 4.9yrs | US$4.94m | 0.064% $ 13.6m | |
| Executive Vice President of International Markets Commercial | 3.3yrs | US$3.73m | 0.028% $ 5.9m | |
| Executive Vice President of European Commercial | 7yrs | US$5.16m | 0% $ 0 | |
| Executive Vice President of Global Operations | less than a year | geen gegevens | geen gegevens | |
| Senior VP & Chief Accounting Officer | 3yrs | geen gegevens | 0.00046% $ 97.8k | |
| Head of Investor Relations | no data | geen gegevens | geen gegevens | |
| Senior Vice President | 2.3yrs | geen gegevens | geen gegevens | |
| Executive VP & Chief Legal Officer | less than a year | geen gegevens | geen gegevens | |
| Executive VP & CHRO | less than a year | geen gegevens | geen gegevens | |
| Senior Vice President of Investor Relations | no data | geen gegevens | geen gegevens | |
| Senior VP & Chief Internal Auditor | 10.5yrs | geen gegevens | geen gegevens |
2.7yrs
Gemiddelde duur
53yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van TEVA wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.7 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | no data | US$25.71m | 0.011% $ 2.3m | |
| Independent Chairman of the Board | 9.8yrs | US$539.99k | 0.036% $ 7.7m | |
| Independent Director | 15.8yrs | US$340.00k | 0.18% $ 39.3m | |
| Independent Director | 9.2yrs | US$355.00k | 0.0094% $ 2.0m | |
| Independent Director | 7.3yrs | US$340.00k | 0.0084% $ 1.8m | |
| Independent Director | 9.2yrs | US$330.00k | 0.0092% $ 1.9m | |
| Independent Director | 4.4yrs | US$325.46k | 0.0056% $ 1.2m | |
| Independent Director | 3.1yrs | US$330.00k | 0.0043% $ 923.0k | |
| Independent Director | 7.3yrs | US$327.87k | 0.0084% $ 1.8m | |
| Independent Director | 6.4yrs | US$315.25k | 0.0078% $ 1.7m | |
| Independent Director | 1.2yrs | US$176.66k | 0.0011% $ 242.4k |
7.3yrs
Gemiddelde duur
64yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van TEVA wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.3 jaar).